Acutus Medical Inc., of Carlsbad, Calif., has launched its Acqblate Force sensing ablation system in Europe, following receipt of the CE mark for its Acqblate Force ablation catheter and the Qubic Force sensing module. The system, which incorporates the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market, also integrates state-of-the-art components make available through Acutus’ alliance with Lake Oswego, Ore.-based Biotronik Inc.: the Qubic Radiofrequency Generator and the Qiona Irrigation Pump.

Cleveland-based companies Canary Health Technologies and Smartshape Design Corp. have teamed up to create Asu Detect CV19, an ultra-rapid, highly accurate breath test device for the detection of COVID-19. The hand-held digital device requires minimal training and can be performed at the point of care, without the need for a laboratory.

Debbie’s Dream Foundation: Curing Stomach Cancer (DDF) said the National Cancer Institute (NCI) has approved its concept for a new gastric cancer research program dedicated to advancing knowledge of the origins of the disease. The new program is expected to speed the trajectory toward new and better treatments and diagnostics. A grant announcement from the NCI will be forthcoming.

Durect Corp., of Cupertino, Calif., said it has signed an agreement to sell its Lactel Absorbable Polymer product line to Evonik Industries AG, of Essen, Germany. Under the terms of the agreement, Evonik will pay Durect $15 million in certain assets and liabilities with the Lactel product line based in Birmingham, Ala., plus an additional potential payment based on full-year EBITDAS results. The deal is expected to close by the first quarter of 2021.

Cambridge, Mass.-based Eurofins Scientific said its FDA-authorized At-Home COVID-19 Nasal PCR Test is now being covered by Medicare, Medicaid and commercial insurance providers. Results are provided via email link within 24 hours of sample receipt.

Carlsbad, Calif.-based Seaspine Holdings Corp. reported the limited release of its Meridian ALIF (anterior lumbar interbody fusion) system and Reef A interbody with Nanometalene surface technology.

Sherlock Biosciences Inc., of Cambridge, Mass., reported the discovery of novel thermostable CRISPR-associated (Cas) enzymes in partnership with researchers at Rosetta Biosciences Inc., of Allston, Mass. According to the company, thermostable Cas proteins enable real-time detection of RNA and/or DNA targets and, when used in tandem with Sherlock’s licensed Cas 12 and Cas 13 enzymes, advance the simultaneous detection of multiple RNA and/or DNA targets in a single test.